This therapy is now FDA approved in adults and is under investigation in children with synovial sarcoma, MPNST and osteosarcoma (NCT05642455) but is limited to MAGE-A4 expressing tumours and HLA-eligible patients. Here, MAGEA4 is linked to synovial sarcoma.